IQVIA Holdings Inc. $IQV Shares Bought by Trajan Wealth LLC

Trajan Wealth LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 13.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,541 shares of the medical research company’s stock after acquiring an additional 17,728 shares during the quarter. IQVIA makes up 1.2% of Trajan Wealth LLC’s holdings, making the stock its 21st largest holding. Trajan Wealth LLC owned about 0.09% of IQVIA worth $28,404,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Physician Wealth Advisors Inc. increased its stake in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. increased its position in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of IQVIA during the third quarter valued at approximately $36,000. Root Financial Partners LLC purchased a new stake in shares of IQVIA in the 3rd quarter valued at approximately $43,000. Finally, Hantz Financial Services Inc. grew its position in IQVIA by 92.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after purchasing an additional 115 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQV stock opened at $165.63 on Monday. The company has a market capitalization of $28.11 billion, a price-to-earnings ratio of 21.07, a P/E/G ratio of 1.60 and a beta of 1.37. The firm has a 50 day moving average of $217.61 and a two-hundred day moving average of $208.66. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of a number of research analyst reports. Stifel Nicolaus reduced their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday. Mizuho set a $266.00 price objective on IQVIA in a research report on Friday, January 9th. Barclays dropped their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a report on Friday, February 6th. Finally, Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $235.20.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.